Search our Database of Scientific Publications and Authors

I’m looking for a

    4295 results match your criteria Urticaria Chronic

    1 OF 86

    Impact of Jumihaidokuto (Shi-Wei-Bai-Du-Tang) on treatment of chronic spontaneous urticaria: A randomized controlled study.
    Chin J Integr Med 2017 Aug 17. Epub 2017 Aug 17.
    Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, 575-0871, Japan.
    Objective: To study the effect of Jumihaidokuto (Shi-Wei-Bai-Du-Tang, ) in the management of chronic spontaneous urticaria.

    Methods: A randomized two-arm, parallel group study was conducted to compare the effect of Jumihaidokuto (6 g daily) with a control for 8 weeks. Concomitant therapy (e. Read More

    Comparison and Interpretability of the available Urticaria Activity Scores.
    Allergy 2017 Aug 16. Epub 2017 Aug 16.
    Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Germany.
    The urticaria activity score (UAS) is the gold standard for assessing disease activity in patients with chronic spontaneous urticaria (CSU). Two different versions, the UAS7 and UAS7TD , are currently used in clinical trials and routine care. To compare both versions and to obtain data on their interpretability, 130 CSU patients applied both versions and globally rated their disease activity as none, mild, moderate, or severe. Read More

    Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice.
    J Allergy Clin Immunol Pract 2017 Aug 9. Epub 2017 Aug 9.
    Personalized Medicine Clinic: Asthma & Allergy-Humanitas Clinical and Research Center, Department of Biomedical Science, Humanitas University, Rozzano, Milan, Italy.
    Background: There is a need for validated tools to assess health-related quality of life (HRQoL) in routine clinical practice.

    Objective: The aim of this study was to validate the Chronic Urticaria Patient Perspective (CUPP) for assessment of patients with chronic urticaria (CU) in clinical practice.

    Methods: A provisional CUPP was developed from candidate items identified by following an iterative process in a retrospective analysis of 249 Chronic Urticaria Quality of Life Questionnaire questionnaires. Read More

    Mast cells are critical for the limitation of thrombin-induced skin inflammation.
    Exp Dermatol 2017 Aug 8. Epub 2017 Aug 8.
    Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany.
    Thrombin, a key player in coagulation, is widely held to induce and promote inflammation. As of now, the features, kinetics, and control of thrombin's proinflammatory effects on the skin remain to be characterized in detail. We, therefore, injected thrombin into the ear skin of mice and observed strong, dose-dependent, and transient ear swelling responses as well as mast cell degranulation. Read More

    Skin diseases of the vulva: eczematous diseases and contact urticaria.
    J Obstet Gynaecol 2017 Aug 7:1-6. Epub 2017 Aug 7.
    a Department of Dermatology , Bispebjerg Hospital , Copenhagen , Denmark.
    Skin diseases in the vulvar area include a variety of disorders many of which have a chronic course with significant morbidity. It is important to be aware of the symptoms, signs and diagnostic tools in order to optimise treatment. Herein, the most common eczematous diseases of the vulvar area, i. Read More

    Histopathological and clinical evaluation of chronic spontaneous urticaria patients with neutrophilic and non-neutrophilic cutaneous infiltrate.
    Allergol Int 2017 Jul 25. Epub 2017 Jul 25.
    Department of Dermatology, Hospital das Clínicas of the University of São Paulo Medical School, São Paulo, Brazil. Electronic address:
    Background: Chronic urticaria has an expressive prevalence in general population, especially in adults, and is defined by the presence of intermittent hives for six weeks or longer. Our study aims to characterize the histological patterns of chronic spontaneous urticaria, based on the inflammatory cell infiltrate, and correlate them to laboratory exams.

    Methods: It was performed a retrospective analysis of laboratory, histopathology and direct immunofluorescence data of 93 patients with chronic urticaria. Read More

    CRP, D-dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria.
    Eur Ann Allergy Clin Immunol 2017 Jul;49(4):189-192
    Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
    Summary: According to current guidelines, non-sedative H1-antihistamines (nsAH) are the first-line therapy of chronic spontaneous urticaria (CSU). But even up-dosed antihistamines (to four times the standard dose) produce symptom resolution in less than 50% of patients. Biomarkers that can predict the response to nsAH are still unknown. Read More

    Effects of omalizumab treatment on serum cytokine concentrations of atopic patients with chronic spontaneous urticaria: a preliminary report.
    Eur Ann Allergy Clin Immunol 2017 Jul;49(4):171-175
    Division of Internal Medicine, Allergy and Clinical Immunology, Department of Medical and Surgical Sciences, Second University of Naples School of Medicine, Naples, Italy. Phone: +39 081 5665 028 Fax: +39 081 5665 080 E-mail:
    Summary: Omalizumab has recently obtained indication for chronic spontaneous urticaria both in the US and Europe. However, the mechanism of action of this drug has yet to be fully elucidated. Previous studies have shown elevations in cytokine serum levels in patients with chronic spontaneous urticaria, and it is not known whether omalizumab treatment may affect cytokine serum levels in this condition. Read More

    Histamine release positive test associates with disease remission in chronic spontaneous urticaria: a proof-of-concept study.
    Eur Ann Allergy Clin Immunol 2017 Jul;49(4):154-160
    Department of Allergy and Clinical Immunology, IRCCS San Raffaele Scientific Institute, Milan, Italy. Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy.
    Summary: Background. Histamine release (HR) test has previously been shown to predict the presence of endogenous histamine-releasing factors in chronic spontaneous urticaria (CSU). Objectives and methods. Read More

    Justification for IgE as a therapeutic target in chronic spontaneous urticaria.
    Eur Ann Allergy Clin Immunol 2017 Jul;49(4):148-153
    Dermatology Service, Centro Médico de Caracas, Caracas, Venezuela.
    Summary: Monoclonal anti-IgE antibodies (omalizumab) are able to induce clinically significant benefits in patients with severe chronic spontaneous urticaria (CS). Those results led clinicians and investigators to reconsider a possible pathogenic role not previously supported for IgE and its receptors in this disease, and to investigate additional approaches for understanding its pathogenesis. IgE antibodies to unknown environmental allergens able to trigger chronic urticaria are not generally regarded as the etiologic factor for the disease. Read More

    Chronic urticaria: a focus on pathogenesis.
    F1000Res 2017 11;6:1095. Epub 2017 Jul 11.
    Medicina Interna, Dipartimento di Fisiopatologia Medico Chirurgica e dei Trapianti, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
    Chronic urticaria is a spontaneous or inducible group of diseases characterized by the occurrence of wheals (and, in about half of cases, angioedema) for more than 6 weeks. These are rather frequent conditions that may severely affect patients' quality of life and sometimes represent a challenge for doctors as well. The causes of chronic urticaria are still poorly defined, although there is growing evidence that different biologic systems including immunity, inflammation, and coagulation may take part in the pathomechanism eventually leading to mast cell and basophil degranulation and hence to wheal formation. Read More

    Omalizumab Treatment in Chronic Inducible Urticaria: A Systematic Review of Published Evidence.
    J Allergy Clin Immunol 2017 Jul 24. Epub 2017 Jul 24.
    Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany.
    Background: Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous urticaria. Evidence is lacking in chronic inducible urticarias (CIndUs), which are frequently H1-antihistamine resistant.

    Objective: We aimed to determine, from the current published literature, the strength of evidence for omalizumab efficacy and safety in the treatment of CIndUs. Read More

    The Burden of Chronic Urticaria from Brazilian Patients' Perspective.
    Dermatol Ther (Heidelb) 2017 Jul 26. Epub 2017 Jul 26.
    Federal University of São Paulo, São Paulo, Brazil.
    Introduction: Chronic urticaria (CU), a proxy for chronic spontaneous urticaria, has been associated with a negative impact on health-related quality of life (HRQoL) and costs, but there is limited evidence on the burden of CU in Brazil. The objective of this study was to estimate the prevalence of CU and assess the burden of CU on HRQoL and healthcare resource utilization (HRU) among adults in Brazil.

    Methods: This retrospective, cross-sectional study, pooled data from the 2011, 2012, and 2015 National Health and Wellness Survey in Brazil (n = 36,000). Read More

    Urticaria and Angioedema: an Update on Classification and Pathogenesis.
    Clin Rev Allergy Immunol 2017 Jul 26. Epub 2017 Jul 26.
    Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland.
    Urticaria is a common, mast cell-driven disease presenting with wheals or angioedema or both. In the last years, urticaria has increasingly attracted notice to clinicians and researchers, last but not least inspired by the approval of omalizumab, an anti-IgE antibody, for urticaria treatment. There is wide consensus on the clinical classification based on duration and elicitation. Read More

    Epidemiology and comorbidities of patients with chronic urticaria in Taiwan‏: A nationwide population-based study.
    J Dermatol Sci 2017 Jul 15. Epub 2017 Jul 15.
    School of Health Care Administration, Taipei Medical University, Taipei, Taiwan. Electronic address:
    Background: Comprehensive data regarding the epidemiology of chronic urticaria (CU) in general populations are scant.

    Objectives: To investigate the prevalence, incidence, and comorbidities of CU in general population.

    Methods: The data were sourced from the National Health Insurance Research Database (NHIRD) for 2009-2012. Read More

    The expanding field of biologics in the management of chronic urticaria.
    J Allergy Clin Immunol Pract 2017 Jul 19. Epub 2017 Jul 19.
    University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address:
    Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternative therapies for refractory cases. Largely based on the success of biologics for various diseases, this class of drugs has come to the forefront of medical research. Read More

    [Chronic urticaria - new views on diagnosis and treatment of disease].
    Cas Lek Cesk 2017 ;156(3):123-126
    Interest in chronic urticaria has grown in recent years, largely owing to the advent of new modes treatment especially in the form of the biologic preparation omalizumab. New scientific and clinical findings have not only facilitated a more comprehensive view of the disease but have streamlined the classification and diagnostic approach as well. Diagnostics are no longer burdened by cumbersome and lengthy investigative procedures into the etiology of urticaria, but are much more rapid and targeted bringing about more timely relief of the patient's symptoms. Read More

    Clinical Outcome of Autologous Serum Therapy in Chronic Idiopathic Urticaria.
    J Nepal Health Res Counc 2017 Jan;15(35):71-74
    Department of Dermatology, Dhulikhel Hospital, Kavre, Nepal.
    Background: Quality of life in chronic idiopathic urticaria is hampered as efficacy of H1-antihistamines is limited. Autologous serum containing tolerance-generating anti-idiotype antibodies is a novel and cost-effective therapy. This study was conducted to evaluate the efficacy of autologous serum therapy (AST) among chronic urticaria patients with autologous skin prick test positive and negative status. Read More

    Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria.
    J Allergy Clin Immunol Pract 2017 Jul 11. Epub 2017 Jul 11.
    Group of Experimental and Clinical Allergy, IPS Universitaria, University of Antioquia, Medellín, Colombia.
    Background: International scientific associations have made recommendations for the management of chronic spontaneous urticaria (CSU) that have been summarized in clinical guidelines.

    Objective: To evaluate the clinical impact of guideline recommendations for CSU management.

    Methods: A multicenter, triple-blinded, prospective, randomized study (the Urticaria Research of Tropical Impact and Control Assessment project; ClinicalTrials. Read More

    Possible role of Helicobacter pylori in diseases of dermatological interest.
    J Biol Regul Homeost Agents 2017 APR-JUN;31(2 Suppl. 2):57-77
    Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
    Helicobacter pylori is a gram-negative, flagellate, microaerophilic bacterium identified for the first time about 30 years ago, as a pathogenic factor of gastritis and peptic ulcer. Soon after, it was linked to several gastrointestinal and extra-gastrointestinal diseases (hematological, cardiovascular, neurological, pulmonary and ocular diseases, obesity, diabetes mellitus, growth retardation and extragastric MALT lymphoma). Association and possible cause-effect correlation with H. Read More

    [Clinical characteristics of urticaria in children versus adults].
    Zhongguo Dang Dai Er Ke Za Zhi 2017 Jul;19(7):790-795
    Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China.
    Objective: To study the clinical characteristics of urticaria in children versus adults, and to provide reference for the etiological analysis, disease evaluation, and treatment of urticaria in children.

    Methods: The clinical data of 2 411 patients with urticaria who visited the Department of Dermatology at Xiangya Hospital of Central South University from January 2013 to May 2017 were collected to study their socio-demographic characteristics. The clinical characteristics of urticaria were compared between the 68 children and 672 adults of the 740 patients with complete follow-up data. Read More

    Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
    Clin Exp Dermatol 2017 Aug 10;42(6):667-669. Epub 2017 Jul 10.
    Allergy Department, Clinica San Carlo, Paderno Dugnano (MI), Milan, Italy.
    Chronic spontaneous urticaria (CSU) is a condition presenting as the spontaneous occurrence of itchy weals with or without angio-oedema for > 6 weeks. A patient with severe chronic spontaneous urticaria who developed resistance to omalizumab is described. The patient's D-dimer plasma levels strictly paralleled the disease activity despite the administration of anti-IgE therapy. Read More

    Burden of Illness and Quality-of-Life Measures in Angioedema Conditions.
    Immunol Allergy Clin North Am 2017 Aug;37(3):597-616
    Allergy Department, Hospital Universitario Severo Ochoa, Avenida de Orellana s/n, Leganés, Madrid 28911, Spain.
    Burden of illness studies and evaluation of health-related quality of life using validated questionnaires have become an important task in the comprehensive management of angioedema conditions, mainly angioedema associated with chronic spontaneous urticaria and hereditary angioedema caused by C1-inhibitor deficiency. A review of the principal tools and studies is presented. Both diseases present a higher proportion of psychiatric disorders, impair work and studies productivity, and produce high direct and indirect costs. Read More

    Histaminergic Angioedema.
    Immunol Allergy Clin North Am 2017 Aug 13;37(3):467-481. Epub 2017 May 13.
    Division of Allergy and Clinical Immunology, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029-6574, USA.
    Angioedema is frequently categorized into histamine- or bradykinin-mediated disease. It is critical to determine the underlying mediator of symptoms as it directs treatment. Histaminergic angioedema is the most frequent cause of angioedema. Read More

    Evaluation of patch test reactivities in patients with chronic idiopathic urticaria.
    Cutis 2017 Jun;99(6):E27-E32
    Immunology Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
    Chronic idiopathic urticaria (CIU) is one of the mysteries of dermatology. An association between spontaneous CIU and contact allergy sensitization is possible. In this study, we aimed to test the hypothesis that contact allergy might play a role in disease in CIU patients. Read More

    Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria.
    J Biol Regul Homeost Agents 2017 Apr-Jun;31(2):407-411
    Department of Internal Diseases, Dermatology and Allergology in Zabrze, SMDZ in Zabrze, Medical University of Silesia in Katowice, Poland.
    Little is known about the role of the kallikrein-kinin system in chronic spontaneous urticaria (CSU). Kallikrein 5 (KLK5), a trypsin-like enzyme, is the most abundant in the skin and plays a role in itching and inflammatory reaction. In this study, we determined plasma KLK5 concentration, and its associations with acute phase response in CSU patients. Read More

    Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014.
    Allergy Asthma Immunol Res 2017 Sep;9(5):438-445
    Department of Allergy and Clinical Immunology, Ajou University School of Medicine and Graduate School of Medicine, Suwon, Korea.
    Purpose: There are very few epidemiological studies on chronic urticaria (CU). We aimed to investigate the prevalence of CU and to depict demographics and medication patterns for the disease in a nationwide population-based study.

    Methods: Data on urticaria (L50 of the International Classification of Diseases, 10th revision) from 2010 to 2014 were obtained from the Korean Health Insurance Review and Assessment Service. Read More

    Acute and Chronic Urticaria: Evaluation and Treatment.
    Am Fam Physician 2017 Jun;95(11):717-724
    University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA.
    Urticaria commonly presents with intensely pruritic wheals, sometimes with edema of the subcutaneous or interstitial tissue. It has a lifetime prevalence of about 20%. Although often self-limited and benign, it can cause significant discomfort, continue for months to years, and uncommonly represent a serious systemic disease or life-threatening allergic reaction. Read More

    Clinical observation on the therapeutic effect of desloratadine citrate disodium in the treatment of chronic urticaria and changes in IL4, IL18, IL23 and IL-33 levels before and after treatment.
    Pak J Pharm Sci 2017 May;30(3(Special)):1139-1142
    Department of Dermatology, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou, China.
    The effect of citrate to Desloratadine Citrate Disodium set in the treatment of chronic urticaria in patients with IL4, IL18, and IL23, IL33 levels was investigated. 100 cases of chronic urticaria treated in our hospital from January 2013 to January 2015 were divided into study group and control group by random number table method. Patients in the study group with chloric thunder of citric acid treatment, the control group were treated with mizolastine in the treatment, the treatment time for 2 weeks. Read More

    Association of altered gut microbiota composition with chronic urticaria.
    Ann Allergy Asthma Immunol 2017 Jul;119(1):48-53
    Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran. Electronic address:
    Background: An altered gut microbiota composition has recently been linked to some types of allergies.

    Objective: To compare the relative amounts of Akkermansia muciniphila, Clostridium leptum, Faecalibacterium prausnitzii, and Enterobacteriaceae as members of gut microbiota among patients with chronic urticaria (CU) and healthy controls.

    Methods: A total of 20 patients with CU and 20 healthy individuals matched by age and sex participated in the study. Read More

    Harefuah 2017 Jun(1):385-389
    Division of Allergy and Clinical Immunology, Bnai Zion Medical Center (affiliated to the Technion Medicine Faculty).
    Introduction: Chronic urticaria is a disease manifested by a pruritic rash lasting longer than 6 weeks that may severely affect quality of life and daily function. Chronic urticaria can be further divided into chronic spontaneous urticaria which appears without a trigger and chronic inducible urticaria which evolves following distinct physical triggers. These two clinical manifestations could coexist in the same patient. Read More

    [Prevalence of urticaria in Cartagena, Colombia].
    Rev Alerg Mex 2017 Apr-Jun;64(2):163-170
    Unidad de Prevención Clínica La Candelaria, Cartagena de Indias, Colombia.
    Background: In Colombia, there have been studies on the prevalence of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis. Prevalence studies of urticaria in Colombia are scarce.

    Objective: Our objective objective of this study was to estimate the prevalence of urticaria in Cartagena (Colombia) in order to contribute to national epidemiological estimates of disease. Read More

    Effectiveness and safety of levocetirizine 10 mg versus a combination of levocetirizine 5 mg and montelukast 10 mg in chronic urticaria resistant to levocetirizine 5 mg: A double-blind, randomized, controlled trial.
    Indian J Dermatol Venereol Leprol 2017 Sep-Oct;83(5):561-568
    Department of Dermatology, Medical College and Hospital, Kolkata, West Bengal, India.
    Background: Chronic urticaria is a vexing problem for patients and treating physicians alike. The EAACI/GA[2]LEN/EDF/WAO guidelines advocate an increased antihistamine dosage up to four times the standard, before adding leukotriene receptor antagonists. Patients are frequently intolerant of these higher dosages. Read More

    Minimum standards on prevention, diagnosis and treatment of occupational and work-related skin diseases in Europe - position paper of the COST Action StanDerm (TD 1206).
    J Eur Acad Dermatol Venereol 2017 Jun;31 Suppl 4:31-43
    Department of Dermatology, Hospital del Mar, Institut Mar d´Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona, Barcelona, Spain.
    Background: Skin diseases constitute up to 40% of all notified occupational diseases in most European countries, predominantly comprising contact dermatitis, contact urticaria, and skin cancer. While insufficient prevention of work-related skin diseases (WRSD) is a top-priority problem in Europe, common standards for prevention of these conditions are lacking.

    Objective: To develop common European standards on prevention and management of WRSD and occupational skin diseases (OSD). Read More

    Advances in atopic dermatitis and urticarial in 2016.
    J Allergy Clin Immunol 2017 Aug 23;140(2):369-376. Epub 2017 Jun 23.
    Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan; Singapore Immunology Network (SIgN) and Institute of Medical Biology (IMB), Agency for Science, Technology and Research (A*STAR), Biopolis, Singapore. Electronic address:
    This review highlights recent key advances in the pathology and therapies of inflammatory skin diseases, focusing on atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). Regarding AD, transcriptomic analysis with human samples revealed different immune profiles between childhood and adult AD. Phase III clinical trials of dupilumab, an anti-IL-4 receptor α antibody, in the treatment of AD have successfully finished, and dupilumab will appear in clinical practice as the first biologic for AD in 2017. Read More

    [IgE and Anti-IgE in Asthma: A Chequered History].
    Pneumologie 2017 Jun 26;71(6):398-405. Epub 2017 Jun 26.
    Abteilung für Pneumologie/Interdisziplinäre Internistische Intensivstation, Zentrum für Innere Medizin, Universität Rostock.
    A long and winding road led to the discovery of immunoglobulin E (IgE) in 1966 and 1967. We are currently on a long and winding road to understand the immunologic basis of the clinical effects of the anti-IgE antibody omalizumab in asthma. It is possible that patients with asthma (as patients with chronic spontaneous urticaria) benefit in different immunologic ways from omalizumab treatment. Read More

    Long-term management of chronic spontaneous urticaria with omalizumab.
    Clin Exp Dermatol 2017 Jun 25. Epub 2017 Jun 25.
    Dermatology Department, Coimbra University Hospital Centre, Coimbra, Portugal.
    Background: Clinical trials have shown the efficacy of omalizumabs efficacy in refractory chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), but real-life management strategies are lacking.

    Aim: To assess the long-term efficacy and safety of omalizumab, and to identify predictive factors and optimum dosage regimens.

    Methods: This was a prospective study of 13 patients (11 women, 2 men) with severe CSU [weekly urticaria activity score (UAS7) > 28] resistant to anti-H1 antihistamines. Read More

    Quantitative in vitro and in vivo models to assess human IgE B cell receptor crosslinking by IgE and EMPD IgE targeting antibodies.
    J Immunol Methods 2017 Jun 21. Epub 2017 Jun 21.
    AFFiRiS AG, Karl-Farkas-Gasse 22, 1030 Vienna, Austria. Electronic address:
    Targeting plasma IgE by therapeutic mABs like Omalizumab (Xolair(®)) is current clinical practice for severe allergic conditions or other IgE related diseases like chronic urticaria. As an alternative to soluble IgE targeting, IgE supply can be lowered by targeting the Extracellular Membrane Proximal Domain (EMPD) of the IgE B cell receptor (BCR) present on IgE switched B cells. This ultimately leads to apoptosis of these cells upon IgE BCR crosslinking. Read More

    Review of Physical Urticarias and Testing Methods.
    Curr Allergy Asthma Rep 2017 Aug;17(8):51
    Allergy and Clinical Immunology Department, Centro Médico Docente La Trinidad, Caracas, Venezuela.
    Purpose Of Review: This review aims to update the information available on the prevalence, clinical picture, diagnostic methods, and treatment of urticarias induced by external physical stimuli.

    Recent Findings: Physical urticarias are present in up to 5% of the general population, and in 10 to 50% of patients with chronic urticaria. Recent investigations have provided evidence that the presence of physical urticaria alone or when comorbid with chronic spontaneous urticaria is associated with a worse prognosis and duration. Read More

    Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria.
    Allergy 2017 Jun 5. Epub 2017 Jun 5.
    Clinical & Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany.
    Background: Chronic urticaria (CU) is a frequent skin disease characterized by relapsing appearance of pruritic hives. While clinical symptoms are due to the release of histamine by cutaneous mast cells, the underlying pathophysiology is still unknown. However, previous studies indicate that basophils might be of relevance. Read More

    Analysis of the changes in Th9 cells and related cytokines in the peripheral blood of spontaneous urticaria patients.
    Biomed Rep 2017 Jun 3;6(6):633-639. Epub 2017 May 3.
    Department of Dermatology, Peking Hepingli Hospital, Beijing 100013, P.R. China.
    Spontaneous urticaria (SU) is characterized by immune deregulation of mast cells and T helper (Th) cells. Th9 cells, a subset of Th cells, serve a key role in initiating mast cell accumulation and activation. To understand the role of Th9 cells in the pathogenesis of SU, the authors conducted a control study of 28 patients with acute SU (ASU) and chronic SU (CSU) and 28 healthy controls. Read More

    Increased serum soluble vascular endothelial cadherin levels in patients with chronic spontaneous urticaria.
    Ann Allergy Asthma Immunol 2017 Jun;118(6):704-709
    Department of Dermato-Venereology, Chengdu Second People's Hospital, Chengdu, Sichuan, China.
    Background: Chronic spontaneous urticaria (CSU) is a common skin disease characterized by recurrent itchy wheals with or without angioedema that lasts longer than 6 weeks. Vascular endothelial (VE)-cadherin is an endothelial cell-specific adhesion molecule that plays critical roles in angiogenesis and endothelial permeability.

    Objective: To investigate serum levels of soluble VE (sVE)-cadherin in patients with CSU. Read More

    Differential expression of microRNAs and their possible roles in patients with chronic idiopathic urticaria and active hives.
    Allergy Rhinol (Providence) 2017 Jun;8(2):67-80
    Background: Chronic idiopathic urticaria (CIU) is a complicated skin disease with unknown pathophysiology. MicroRNAs (miRNA) have been shown to be active in cellular regulation. The goal of this pilot study was to examine whether miRNAs may be involved in the regulation of CIU or as biomarkers for CIU. Read More

    The use of skin biomarker profiles to distinguish Schnitzler's syndrome from chronic spontaneous urticaria: results of a pilot study.
    Br J Dermatol 2017 Jun 5. Epub 2017 Jun 5.
    Dept. of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Germany.
    urticarial rash is a hallmark symptom of systemic autoinflammatory diseases such as Schnitzler's syndrome (SchS). Clinically, the urticarial rash cannot be distinguished from wheals in chronic spontaneous urticaria (CSU). Thus, it is commonly misdiagnosed as CSU. Read More

    Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.
    J Eur Acad Dermatol Venereol 2017 Jun 2. Epub 2017 Jun 2.
    Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
    Background: Chronic spontaneous/idiopathic urticaria (CSU/CIU) has substantial detrimental effects on health-related quality of life (HRQoL) with an effect comparable to or worse than many other skin diseases.

    Objective: To assess the effect of omalizumab on CSU patients' HRQoL, measured by the Dermatology Life Quality Index (DLQI) in three phase III studies ASTERIA I, ASTERIA II and GLACIAL.

    Methods: A post hoc analysis examined changes in DLQI scores, distribution of patients across DLQI bands and the proportion reaching minimal clinically important difference (MCID) following omalizumab vs. Read More

    Patient-reported outcomes (PROs) in chronic urticaria.
    Int J Dermatol 2017 Jun 1. Epub 2017 Jun 1.
    Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
    Chronic urticaria is an itching skin disease which persists for more than 6 weeks. Chronic urticaria has great impact on the daily life of the patient, and the fluctuating nature of the symptoms complicates the monitoring and treatment of the disease. Currently, there are no reliable biomarkers to identify and measure disease activity in chronic spontaneous urticaria. Read More

    Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients.
    Allergol Int 2017 May 26. Epub 2017 May 26.
    Division of Allergy and Clinical Immunology, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey.
    Background: Previous data have shown the high efficacy of omalizumab in chronic spontaneous urticaria (CSU). However, factors that may be effective on the response to therapy, relapse rates after drug discontinuation, and efficacy of retreatment remain unclear. This study aimed to determine the efficacy of omalizumab in CSU refractory to conventional therapy, to identify possible factors affecting treatment response and relapse, and also to evaluate the efficacy of retreatment on relapsed disease. Read More

    1 OF 86